共 50 条
- [31] Ascending Dose Trials of a Retroviral Replicating Vector (Toca 511) in Patients with Recurrent High-Grade Glioma: Clinical Update, Molecular Analyses, and Proposed Mechanism of ActionMOLECULAR THERAPY, 2016, 24 : S27 - S27Jolly, Douglas J.Robbins, Joan M.Ostertag, DerekIbanez, CarlosKasahara, NoriyukiGruber, HarryKalkanis, Steven N.Vogelbaum, MichaelAghi, Manish K.Cloughesy, TimothyChu, AliceDas, AshaSkillings, Jamey
- [32] A RT-qPCR Diagnostic System to Monitor Toca 511, a Cancer-selective Gene Therapy for the Treatment of Patients with Recurrent High-grade Glioma.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Sudin, ErikWang, ZuguangWang, AprilgateWeitz, SaraSidhu, HarwinderShields, AileenChen, JosephShields, MalcolmOstertag, DerekUzgiris, Arejas James
- [33] BRAINWEAR: LONGITUDINAL, OBJECTIVE ASSESSMENT OF PHYSICAL ACTIVITY IN 42 HIGH GRADE GLIOMA (HGG) PATIENTSNEURO-ONCOLOGY, 2021, 23 : 3 - 3Dadhania, SeemaPakzad-Shahabi, LillieLe Calvez, KerlannSaleem, WaqarWang, JamesMohammed, WaleedMistry, SanjayWilliams, Matthew
- [34] Phase II study of sunitinib and irinotecan in patients with recurrent high-grade glioma (HGG).JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Grisanti, S.Pedersini, R.Ferrari, V. D.Liserre, R.Consoli, F.Poliani, L.Boglione, M.Rangoni, G.Montini, E.Simoncini, E.
- [35] Clinical update, molecular analyses, and proposed mechanism of action of Toca 511 a retroviral replicating vector in three ascending dose trials in patients with recurrent high-grade gliomaHUMAN GENE THERAPY, 2016, 27 (11) : A41 - A41Jolly, D. J.Ostertag, D.Hogan, D.Ibanez, C.Mitchell, L.Yagiz, K.Kasahara, N.Gruber, H.Kalkanis, S. N.Vogelbaum, M.Aghi, M. K.Cloughesy, T.Das, A.
- [36] THE TOCA 7 STUDY: PHASE 1B STUDY OF TOCA 511, A LIVE GAMMA RETROVIRUS, AND TOCA FC, AN EXTENDED-RELEASE FORMULATION OF 5-FLUOROCYTOSINE COMBINED WITH STANDARD OF CARE IN NEWLY DIAGNOSED HIGH GRADE GLIOMA (NCT02598011)NEURO-ONCOLOGY, 2016, 18 : 2 - 2Vogelbaum, MichaelLassman, AndrewLee, IanLiau, LindaSonabend, AdamWalbert, TobiasYang, LiqiangDas, AshaCloughesy, Timothy
- [37] Long-Term Follow-Up Data from 126 Patients with Recurrent High Grade Glioma from Three Phase 1 Trials of Toca 511 and Toca FC: Update and Justification for a Phase 2/3 TrialMOLECULAR THERAPY, 2017, 25 (05) : 24 - 25Jolly, Doug J.Aghi, ManishVogelbaum, Michael A.Kalkanis, Steven N.Bota, DanielaChen, Clark C.Carter, BobElder, BradEngh, JohnathanGoldlust, Samuel A.Kaptain, George J.Kesari, SantoshLandolfi, JosephLiau, Linda M.Mikkelsen, TomPiccioni, DavidPortnow, JanaSinger, SamuelWalbert, TobiasGruber, HarryIbanez, CarlosMitchell, LeahOstertag, DerekShorr, Jolene S.Yang, LiqiangDas, AshaCloughesy, Timothy F.
- [38] LONG-TERM FOLLOW-UP DATA FROM 126 PATIENTS WITH RECURRENT HIGH GRADE GLIOMA FROM THREE PHASE 1 TRIALS OF TOCA 511 AND TOCA FC: UPDATE AND JUSTIFICATION FOR A PHASE 2/3 TRIALNEURO-ONCOLOGY, 2017, 19 : 19 - 19Aghi, M.Vogelbaum, M. A.Kalkanis, S. N.Bota, D.Piccioni, D.Elder, B.Engh, J.Kaptain, G. J.Landolfi, J.Cloughesy, T. F.
- [39] Long-term follow-up data from 123 patients with recurrent high grade glioma from three Phase 1 trials of Toca 511 and Toca FC: Update and justification for a Phase 2/3 trialJOURNAL OF NEUROSURGERY, 2017, 126 (04) : A1414 - A1414Huang, Tiffany T.Aghi, ManishVogelbaum, MichaelKalkanis, StevenBota, DanielaCarter, BobChen, ClarkElder, BradleyKaptain, GeorgeKesari, SantoshCloughesy, TimothyWalbert, Tobias
- [40] PHASE 1 TRIAL OF A RETROVIRAL REPLICATING VECTOR (TOCA 511) IN RECURRENT HIGH GRADE GLIOMA PATIENTS DEMONSTRATES THE IMPORTANCE OF REAL-TIME MRI-GUIDED DELIVERY FOR DOSE-RELATED EVALUATION OF SAFETY AND EFFICACYNEURO-ONCOLOGY, 2013, 15 : 217 - 217Aghi, ManishVogelbaum, Michael A.Jolly, Douglas J.Robbins, Joan M.Ostertag, DerekIbanez, Carlos E.Gruber, Harrry E.Kasahara, NoriyukiBankiewicz, KrystofCloughesy, Timothy F.Chang, Susan M.Butowski, NicholasKesari, SantoshChen, ClarkMikkelsen, TomLandolfi, JosephChiocca, E. AntonioElder, J. BradleyFoltz, GregPertschuk, Dan